Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2010 - 2026)

Celldex Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 52.93% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $51.9 million (up 52.93% YoY), while the FY2025 annual figure was $51.8 million, up 23.68% from the prior year.
• Total Non-Current Liabilities was $51.9 million for Q1 2026 at Celldex Therapeutics, roughly flat from $51.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $51.9 million in Q1 2026 to a low of $15.4 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $31.4 million across 5 years, with a median of $32.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 104.19% in 2022, then slumped 46.61% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $21.2 million in 2022, then soared by 51.21% to $32.1 million in 2023, then surged by 30.6% to $41.9 million in 2024, then increased by 23.68% to $51.8 million in 2025, then rose by 0.27% to $51.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $51.9 million (Q1 2026), $51.8 million (Q4 2025), and $47.5 million (Q3 2025), per Business Quant data.